U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088263) titled 'Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer' on July 20.
Brief Summary: The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
Study Start Date: Aug. 04
Study Type: INTERVENTIONAL
Condition:
Breast Neoplasms
Intervention:
DRUG: Gemcitabine, Vinorelbine, Eribulin, or Utidelone
Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Sun Yat-sen University
Infor...